A phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha protocol CSTI5710110 (Novartis)

Trial Profile

A phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha protocol CSTI5710110 (Novartis)

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2011

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia; Myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 09 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top